Meningococcal Disease Drugs Market

Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of death associated with infection. Infection of Neisseria meningitidis may also result in mental retardation, deafness and epilepsy. 12 strains of N. meningitidis have been identified, 6 of which (A, B, C, W, X and Y) are capable enough to cause epidemics. Meningococcal septicaemia is a rare but fatal form of meningococcal disease characterized by a haemorrhagic rash and rapid circulatory collapse.

Meningococcal Disease Drugs Market contains market size and forecasts of Meningococcal Disease Drugs in global, including the following market information:

• Global Meningococcal Disease Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Meningococcal Disease Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Meningococcal Disease Drugs companies in 2021 (%)

The global Meningococcal Disease Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Injectable Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Meningococcal Disease Drugs include Pfizer, GlaxoSmithKline, Sanofi Pasteur, Novartis, Merck Sharp & Dohme, Hebei Hejia Pharmaceutical Technology Group Co., Ltd, Shandong Jincheng Pharmaceutical Group Co.,ltd., Apeloa Pharmaceutical Co.,Ltd. and Yiling Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Meningococcal Disease Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Meningococcal Disease Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Meningococcal Disease Drugs Market Segment Percentages, by Type, 2021 (%)

• Injectable
• Oral

Global Meningococcal Disease Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Meningococcal Disease Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Drugstores
• Others

Global Meningococcal Disease Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Meningococcal Disease Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Meningococcal Disease Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Meningococcal Disease Drugs revenues share in global market, 2021 (%)
• Key companies Meningococcal Disease Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Meningococcal Disease Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• GlaxoSmithKline
• Sanofi Pasteur
• Novartis
• Merck Sharp & Dohme
• Hebei Hejia Pharmaceutical Technology Group Co., Ltd
• Shandong Jincheng Pharmaceutical Group Co.,ltd.
• Apeloa Pharmaceutical Co.,Ltd.
• Yiling Pharmaceutical
• Baiyunshan Pharmaceutical
• SSY Group Limited
• Lukang Pharmaceutical Co.,Ltd.
• North China Pharmaceutical Company Ltd.
• Harbin Pharmaceutical Group Co.,Ltd.